22 de agosto de 2019
22 de julio de 2010

Kowa Announces Successful EU Regulatory Application for Pitavastatin (y 2)


1) F Peter Guengerich; Cytochrome P450 and Chemical Toxicology.
Chem.Res.Toxicol.2008, 21, 70-83
2) Budinski D, Arneson V, Hounslow N, et al., Pitavastatin compared
with atorvastatin in primary hypercholesterolemia or combined
dyslipidemia Clinical Lipidology 2009,4;3:291-302
3) Budinski D, Arneson V, Hounslow N, et al., Comparison of
pitavastatin with simvastatin in primary hypercholesterolaemia or
combined dyslipidaemia Current Medical Research and Opinion
2009,25;11:2755-2764
4) Stender S, Hounslow N. Robust efficacy of pitavastatin and
comparable safety to pravastatin. Atherosclerosis Suppl. 2009, Vol. 10,
Issue 2
5) Data on file (304,309).
6) Ose L, Budinski D, Hounslow N, Arneson V: Long-term treatment
with pitavastatin is effective and well tolerated by patients with
primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis
2010; 202-208

Dr Rod Coombs, European Marketing Manager, Mobile: +44(0)7824-415025, Direct Line: +44(0)118-922-9013, E Mail: rcoombs@kowa.co.uk